Amphastar Pharmaceuticals, Inc. (AMPH) News
Filter AMPH News Items
AMPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AMPH News Highlights
- AMPH's 30 day story count now stands at 16.
- Over the past 27 days, the trend for AMPH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about AMPH are AMP, MIST and NOTE.
Latest AMPH News From Around the Web
Below are the latest news stories about AMPHASTAR PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMPH as an investment opportunity.
Zacks.com featured highlights include Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa HoldingsTecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings are part of the Zacks Screen of the Week article. |
The Cream Of The Crop: 5 Biotechs That Outrank Most StocksThe top five biotech stocks today have several commonalities. Among them are Strong ratings. Some show promising charts and are Tech Leaders. |
4 Solid Profitable Stocks to Invest in Using Net Income RatioTecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH), Turkcell Iletisim Hizmetleri (TKC) and Copa Holdings (CPA) have been selected as the top picks with a high net income ratio. |
IBD 50 Stock Hits All-Time High, And 44% EPS Growth ExpectedThis drug stock ranks first out of 790 medical stocks and is in the buy zone. The company plans to roll out its overdose nasal spray in the third quarter. |
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare ConferenceAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 2:30 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . |
Amphastar Pharmaceuticals (NASDAQ:AMPH) shareholders have earned a 22% CAGR over the last five yearsWhen you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose... |
Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva PharmaceuticalAmphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article. |
Looking for a Growth Stock? 3 Reasons Why Amphastar (AMPH) is a Solid ChoiceAmphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market. |
3 Generic Drug Stocks to Watch Amid Macro HeadwindsThe impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA. |
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year. |